Dosage Forms

Feliza Mirasol is the science editor for 

Articles

This $4.1 billion investment to build a second fill/finish manufacturing facility in Clayton, N.C., boosts Novo Nordisk's current 2024 investments in production to $6.8 billion.

Novo Nordisk Aims to Invest $4.1 Billion to Expand Manufacturing Capacity in US

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

Automating the Future of Fill/Finish

Takeda has received FDA approval for HYQVIA, a subcutaneous immunoglobulin for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.

Takeda’s Subcutaneous Immunoglobulin Receives FDA Approval for Maintenance Therapy of Rare Neuromuscular Disorder

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Pharmaceutical Technology Europe® spoke with Joren van der Horst from Luo Automation, a Dutch company focused on automated visual inspection solutions, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

Making Visual Inspection Accessible with Luo Automation at CPHI Barcelona

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Advent International, Warburg Pincus Complete $4.25 Billion Acquisition of Baxter’s BioPharma Solutions Business

Dosage forms are being shaped by numerous factors, with patient-centricity continuing to be an important driver of decisions in development.

Driving Dosage Form Developments

Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.

Takeda Gets Approval in Japan for Entyvio Subcutaneous Injection 

Lubrizol has launched Apisolex technology to improve solubility and simplify the manufacturing of parenteral drug products.

Lubrizol Launches Apisolex Technology 

Eli Lilly and Company is investing $1 billion to establish a new manufacturing site in Concord, NC, to manufacture parenteral products and devices.

Lilly to Invest $1 Billion to Build New Parenteral Manufacturing Facility in North Carolina

In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.

Parenterals